New Developments in Myeloma An Issue of Hematology/Oncology Clinics of North America

In this issue of <i>Hematology/Oncology Clinics</i>, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of <b>New Developments in Myeloma</b>. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.<ul><li>Contains <b>16 relevant, practice-oriented topics</b> including molecular pathogenesis of multiple myeloma; monoclonal antibodies in the treatment of multiple myeloma; CAR-T cells in the treatment of multiple myeloma; management of newly diagnosed multiple myeloma today, and in the future; approach to high-risk multiple myeloma; new therapies on the horizon for relapsed refractory multiple myeloma; and more.</li><li>Provides in-depth <b>clinical reviews on new developments in myeloma</b>, offering actionable insights for clinical practice.</li><li>Presents the <b>latest information on this timely, focused topic</b> under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.</li></ul>